# VITL surpasses USD 10 million in ARR

On 2026/3/26, TechCrunch reported that VITL, a prescribing platform for cash-pay clinics, completed USD 7.5 million in funding and exceeded USD 10 million in annual recurring revenue, benefiting from demand for GLP-1 drugs.



Canonical: https://uniquebase.ai/news/06803386-2575-4d0c-8efc-d4e049f1d4d4
Stable identifier: 06803386-2575-4d0c-8efc-d4e049f1d4d4
Snapshot captured: 2026-10-18T08:51:49.337Z
English updated: 2026-10-18T08:52:13.982Z

## Connected profiles

- [SignalFire](/institutions/signalfire)
- [VITL](/companies/vitl)

## Sources

- https://techcrunch.com/2026/03/25/riding-the-glp-1-boom-vitl-lands-7-5m-to-overhaul-cash-pay-clinic-prescribing/